Literature DB >> 9512057

The role of accumbens dopamine in lever pressing and response allocation: effects of 6-OHDA injected into core and dorsomedial shell.

J D Sokolowski1, J D Salamone.   

Abstract

Three experiments investigated the behavioral effects of injections of the neurotoxic agent 6-hydroxydopamine (6-OHDA) into the core or shell of the nucleus accumbens. In the first experiment, it was observed that injections of 6-OHDA into either core or shell had no significant effect on variable interval 30-s responding. In Experiment 2, responding on a fixed ratio 5 (FR5) schedule was impaired by 6-OHDA injections in the core, but not the shell. Rats with core injections of 6-OHDA showed significant alterations in the relative distribution of interresponse times, which were indicative of reductions in the maximal rate of responding and increases in the number of pauses. In the third experiment, rats were tested using a lever-pressing/chow-feeding procedure, in which a preferred food (Bioserve pellets) was available by pressing a lever on a FR5 schedule, but a less preferred food (lab chow) was also available concurrently in the test chamber. Untreated rats usually pressed the lever at high rates to obtain the food pellets and ate little of the lab chow. After training, dopamine depletions were produced by injections of 6-OHDA directly into the core or dorsomedial shell subregions. Injections of 6-OHDA into the core significantly decreased lever pressing for food pellets, increased lab chow consumption, and decreased the relative amount of food obtained by lever pressing. Dorsomedial shell injections of 6-OHDA had no significant effects on either lever pressing or lab chow consumption. Neurochemical results indicate that injections of 6-OHDA in the shell produced substantial depletions in the shell that were somewhat selective; however, injections of 6-OHDA into the core tended to deplete both core and shell. Correlational analyses revealed that decreases in FR5 lever pressing were associated with dopamine levels in the core, but not the shell. The present results indicate that substantial depletions of dopamine in the dorsomedial shell are not sufficient for suppressing reinforced lever pressing, and indicate that dopamine depletions must include the core area to impair performance on these tasks. The lack of effect of accumbens dopamine depletions on VI30 responding are consistent with the notion that accumbens dopamine depletions affect responding on schedules that generate a high rate of responding (FR5), but not those that generate a moderate rate of responding (e.g., VI30 s). The results of the concurrent FR5/chow-feeding experiment indicate that rats with accumbens dopamine depletions remain directed towards the acquisition and consumption of food. These results suggest that dopamine in the core region of accumbens sets constraints upon the selection of food-related behaviors, and that core dopamine depletions alter the relative allocation of food-related responses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9512057     DOI: 10.1016/s0091-3057(97)00544-3

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  51 in total

1.  Evidence that separate neural circuits in the nucleus accumbens encode cocaine versus "natural" (water and food) reward.

Authors:  R M Carelli; S G Ijames; A J Crumling
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

Review 2.  The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond.

Authors:  John D Salamone; Merce Correa; Eric J Nunes; Patrick A Randall; Marta Pardo
Journal:  J Exp Anal Behav       Date:  2012-01       Impact factor: 2.468

Review 3.  Calculating utility: preclinical evidence for cost-benefit analysis by mesolimbic dopamine.

Authors:  Paul E M Phillips; Mark E Walton; Thomas C Jhou
Journal:  Psychopharmacology (Berl)       Date:  2006-11-22       Impact factor: 4.530

4.  The role of dopamine in reinforcement: changes in reinforcement sensitivity induced by D1-type, D2-type, and nonselective dopamine receptor agonists.

Authors:  Natalie A Bratcher; Valeri Farmer-Dougan; James D Dougan; Byron A Heidenreich; Paul A Garris
Journal:  J Exp Anal Behav       Date:  2005-11       Impact factor: 2.468

5.  Facilitated extinction of appetitive instrumental conditioning following excitotoxic lesions of the core or the medial shell subregion of the nucleus accumbens in rats.

Authors:  Helen H J Pothuizen; Joram Feldon; Benjamin K Yee
Journal:  Exp Brain Res       Date:  2006-01-24       Impact factor: 1.972

Review 6.  Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits.

Authors:  J D Salamone; M Correa; A Farrar; S M Mingote
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

7.  Forebrain circuitry involved in effort-related choice: Injections of the GABAA agonist muscimol into ventral pallidum alter response allocation in food-seeking behavior.

Authors:  A M Farrar; L Font; M Pereira; S Mingote; J G Bunce; J J Chrobak; J D Salamone
Journal:  Neuroscience       Date:  2008-01-01       Impact factor: 3.590

8.  Dopamine dependency for acquisition and performance of Pavlovian conditioned response.

Authors:  Martin Darvas; Amanda M Wunsch; Jeffrey T Gibbs; Richard D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

9.  Adenosine A(2A) receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing.

Authors:  Andrew M Farrar; Mariana Pereira; Francisco Velasco; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2006-10-27       Impact factor: 4.530

10.  Restricting dopaminergic signaling to either dorsolateral or medial striatum facilitates cognition.

Authors:  Martin Darvas; Richard D Palmiter
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.